What Femaston (Estradiol) Treats: Main Uses and Benefits

Femoston is relevant in clinical settings involving symptoms related to oestrogen deficiency in postmenopausal women with an intact uterus. The primary therapeutic indications include the relief of symptoms occurring after menopause and the prevention of osteoporosis in postmenopausal women at high risk of future fractures. The medication is relevant in clinical settings involving symptoms that create noticeable physiological strain.

Addressing Disruptive Vasomotor Symptoms

Femoston is commonly used to help with symptomatic relief for groups of symptoms that may become intense or disruptive, primarily hot flushes and drenching night sweats. By assisting with the management of these systemic episodes, the medication helps ease the overall symptom load and supports patients during episodes of heightened discomfort.

Supporting Emotional Stability and Sleep Quality

This therapy is relevant for easing the associated cluster of neuropsychological symptoms, including mood fluctuations, increased irritability, and persistent sleep disruption. Providing support in this domain may assist with managing the functional stability when symptoms are more noticeable, helping patients cope more steadily with symptom fluctuations.

Long-Term Prevention of Bone Density Loss

The medication is considered relevant for its supportive structural and preventative benefit, applicable in conditions involving bone loss where supportive symptom management is appropriate. This use provides supportive relief that contributes to easing the potential risk of fragility fractures in conditions characterized by periods of heightened bone loss.

---

Quick Fact: Relief for Hot Flushes and Night Sweats (Vasomotor Symptoms).

Official Eligibility for Femaston

The use of Femaston (Estradiol/Dydrogesterone) is strictly defined by regulatory guidelines that govern the approved population and list absolute contraindications.

Populations Allowed and Restricted

Category	Regulatory Status
Target Population	Postmenopausal women with an intact uterus [1.1].
Age Restriction	Not recommended for the pediatric population (under 18 years); safety is not established [2.2]. Experience in women over 65 years is limited [3.3].
Pregnancy/Lactation	Contraindicated during pregnancy [1.1]; Not recommended during lactation [1.3].

Absolute Contraindications

Treatment with Femaston is prohibited for patients with certain specific conditions or history, as stated in official labeling:

• Malignancy History: Known, past, or suspected breast cancer or other hormone-dependent malignant tumours [1.1].
• Thromboembolic History: Previous or current venous thromboembolism (VTE), arterial thromboembolic disease (e.g., stroke), or known thrombophilic disorders [2.4].
• Current Acute Conditions: Acute liver disease (until liver function tests normalize), undiagnosed genital bleeding, or untreated endometrial hyperplasia [2.2].

Use requires close supervision and potential withdrawal for patients with conditions like hypertension, diabetes mellitus, or migraine [2.3].

Interactions with other medicines and products

Pharmacokinetic Interaction Patterns

The interaction profile of Femoston (Estradiol/Dydrogesterone) is defined primarily by its involvement with the Cytochrome P450 (CYP) enzyme system, as documented in regulatory information. Co-administration with drugs classified as CYP3A4 inducers (substances that increase enzyme activity) may cause an increased metabolism of both the oestrogen and progestogen components. This pharmacokinetic interaction can lead to a reduction in plasma concentrations of the hormones and a resulting decrease in therapeutic effect.

Conversely, the oestrogen component of this therapy is documented as an inhibitor of certain CYP enzymes, including CYP3A4 and CYP1A2. This inhibition can lead to an increase in the plasma levels of co-administered drugs that are substrates of these enzymes, potentially raising their concentrations.

Specific Interacting Substances

Specific co-administered substances that may experience this increased plasma level include Tacrolimus, Cyclosporine A, Fentanyl, and Theophylline. Separately, the medication Sugammadex is documented to cause a significant decrease in progestogen exposure. Furthermore, oestrogen is expected to cause a significant decrease in the plasma concentration of Lamotrigine due to enhanced clearance, which may lead to a reduction in its intended effect.

Administration Context

Regulatory documentation confirms that Femoston can be taken with or without food, indicating an absence of a mandatory administration-timing rule based on meal intake.

Receptor-Mediated Genomic Signaling

Femoston contains estradiol, which acts as an agonist by binding to and activating the specific intracellular estrogen receptors ( ERalpha and ERbeta) found in target cells across multiple systems. This receptor-ligand complex then translocates to the cell nucleus, where it modulates the transcription of key genes. This engagement initiates or suppresses signaling sequences that lead to broad systemic physiological outcomes, resulting in the modulation of downstream cellular processes, including those regulating mineral homeostasis and neuronal excitability.

Endometrial Protective Mechanism

The second component, dydrogesterone, is an orally active progestogen that binds to the progesterone receptor. This binding initiates a distinct set of gene expression changes within the cells lining the uterus (the endometrium). Dydrogesterone's role is to promote endometrial differentiation into a secretory phase. This process mitigates the unopposed estrogen-mediated cell proliferation by altering gene expression profiles within the endometrium, modulating the cyclical transformation of the uterine lining.

Femaston is administered as a continuous sequential Hormone Replacement Therapy (HRT) using film-coated tablets for oral intake. The regimen is designed as a 28-day cycle with no break between packs, and is specifically indicated for postmenopausal women with an intact uterus.

---

Official Dosing and Scheduling

Parameter	Instruction
Route & Form	Oral film-coated tablets.
Dosing Regimen	One tablet taken once daily (OD) from the blister pack.
Strength Options	Two common strengths are: Estradiol 1 mg / Dydrogesterone 10 mg (e.g., Femoston 1/10) and Estradiol 2 mg / Dydrogesterone 10 mg (e.g., Femoston 2/10).
Timing & Food	Tablets should be taken at the same time each day and can be taken with or without food.
Missed Dose Rule	If a dose is forgotten, it should be taken as soon as possible, but only if less than 12 hours have elapsed since the scheduled time. If the delay exceeds 12 hours, the missed dose should be skipped, and the treatment should continue with the next tablet at the regular time.

---

The continuous sequential regimen consists of two phases within the 28-day cycle. For the first 14 days, the patient takes the estradiol-only tablet; for the subsequent 14 days, the patient takes the tablet containing both estradiol and dydrogesterone. Patients typically start with the lower estrogen dose (1 mg/10 mg), with the dose being adjusted if necessary, based on the response to the estrogen component.

Research evidence / Overview of studies for Femaston (Estradiol)

---

Research Evidence for Relief of Moderate-to-Severe Menopausal Symptoms

Clinical evaluation has focused on short-term, double-blind, randomized, placebo-controlled trials (RCTs). This research was studied for postmenopausal women with an intact uterus, usually between 40 and 65 years old, who reported experiencing frequent, noticeable hot flushes and night sweats.

Researchers monitored outcomes related to physical discomfort by tracking the number and severity of vasomotor symptoms. Findings describe patterns observed in the studies where research describes changes measured during the study period. These core trials focused on short-term changes; however, evidence remains limited regarding the longer-term durability of these observed effects beyond the initial study periods of approximately 12 to 13 weeks.

Research Evidence for Endometrial Protection

Clinical programs involved open-label, multicentre studies and long-term safety components embedded within broader trials. The research was evaluated in non-hysterectomized postmenopausal women receiving the combined continuous treatment. Studies monitored the key structural outcomes related to the uterine lining.

Research describes the established role of the progestogen component. Research describes the patterns observed where the combination was associated with maintenance of the uterine lining structure. Comparative evidence is lacking against all alternative hormonal and non-hormonal therapies regarding long-term endometrial protection.

Research Evidence for Prevention of Bone Density Loss

Studies explored outcomes related to systemic or functional imbalance, specifically monitoring changes in Bone Mineral Density (BMD) at specific skeletal sites. The data show patterns related to how bone density evolved in the observed populations. The results apply only to the populations studied, as the indication for osteoporosis prevention is typically limited to specific groups of postmenopausal women identified as being at a high risk for future fractures. Comparative evidence is lacking across all potential patient groups.

---

What Remains Uncertain in the Research Landscape

While research provides context regarding the broader evidence landscape, certainty remains low in several areas related to long-term outcomes. Data for certain groups remain insufficient, as few data are available for women starting therapy who are older than 65 years of age. Research is ongoing.

Key Studies & References

1. Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms
2. Public Assessment Report Decentralised Procedure Femoston-conti 0.5mg/2.5mg, Film-coated Tablets Estradiol hemihydrate/Dydrogesterone (Regulatory Document providing summary of clinical data)

Common questions about Femaston (Estradiol) (FAQ)

---

Q: Is Femaston the same thing as just 'estrogen' therapy?

Femaston is not a single-component estrogen product. According to official documents, it is a combination Hormone Replacement Therapy (HRT) that contains two active ingredients: an oestrogen, Estradiol, and a progestogen, Dydrogesterone. This combination is typically prescribed for women who still have their uterus.

---

Q: What is the difference between Femaston and other common HRT brands?

Official product information defines Femaston by its specific components and treatment type. It is classified as a continuous sequential combination HRT that uses the specific hormones Estradiol and Dydrogesterone. Regulatory documents describe the product by its unique active ingredients and dosing structure, but they do not provide comparisons to other brands.

---

Q: Can Femaston cause weight gain?

Weight changes are listed in official safety documents as a Common side effect, affecting up to 1 in 10 women. This means that a person may experience either an increase or a decrease in weight while using the medicine.

---

Q: How long does it usually take to notice any effects from Femaston?

Many women notice an improvement in their symptoms within a few weeks of starting treatment. However, official information indicates that it can sometimes take up to three months for the body to adjust to the treatment and for any effects to become noticeable.

---

Q: Is it normal to experience spotting or bleeding while using Femaston?

Yes, menstrual disorders, including spotting or breakthrough bleeding, are classified as a Very Common side effect, affecting 1 in 10 or more women. This often occurs during the initial months of treatment as the body adjusts to the sequential hormonal regimen.

---

Q: Does Femaston affect mood or cause emotional changes?

Official safety documents list changes in emotional state as potential effects. Both depressive mood and nervousness are classified as Common side effects, meaning they may affect up to 1 in 10 women using the therapy.

---

Q: Can I use natural or herbal supplements while taking Femaston?

Regulatory documents state that co-administration with substances that are CYP3A4 inducers may lead to a reduction in the plasma concentrations of the hormones in Femaston. This includes certain herbal supplements, such as St. John's Wort. The effect of the medicine may be reduced as a result of lower hormone levels.

---

Q: Does Femaston have different safety warnings compared to other HRT medicines?

The safety profile of Femaston includes warnings for risks that are considered class effects of combined Hormone Replacement Therapy (HRT). These risks include an increased risk of Venous Thromboembolism (blood clots), stroke, and certain cancers. These warnings apply broadly to this type of medication.

---

Q: Can smoking affect how Femaston works or its safety?

Official guidelines suggest that smoking is generally considered a pre-existing risk factor for increased thromboembolic or cardiovascular events in individuals using oestrogen-containing therapy. This concern is particularly noted for women over age 35 who smoke.

---

Q: Does Femaston have any known interactions with commonly prescribed antidepressants?

The oestrogen component in Femaston is documented as an inhibitor of certain enzymes in the liver, such as CYP1A2. This inhibition could potentially lead to an increase in plasma levels of co-administered drugs that are processed by these enzymes, requiring consideration when prescribing these medicines together.

---

Q: What if I start my period while I am taking Femaston?

Bleeding or spotting is expected to occur in the first months of treatment with the sequential regimen. If break-through bleeding or spotting starts after some time on therapy or continues after treatment has been discontinued, official guidelines note that a healthcare professional should investigate the reason.

---

Q: Can Femaston be broken in half or crushed?

Femaston is described in regulatory information as film-coated tablets intended to be swallowed whole. Official documents do not provide any instructions for splitting, crushing, or otherwise altering the tablets.

---

Q: Are there any known differences in how Femaston affects people based on age?

The experience from clinical studies in treating women older than 65 years is officially described as limited. The medication is indicated for postmenopausal women, and the safety and benefit profile for individuals in older age groups may require careful evaluation.

---

Q: How does the research characterize the risk of blood clots with this type of medicine?

Official safety documents state that Hormone Replacement Therapy (HRT) is associated with an increased risk of Venous Thromboembolism (VTE), which includes Deep Vein Thrombosis and Pulmonary Embolism. This risk is officially noted to be associated with the duration of HRT use.

---

Q: Is Femaston considered a 'natural' or 'bio-identical' hormone?

The oestrogen component in Femaston, Estradiol, is chemically and biologically identical to the main oestrogen hormone naturally produced by the human body. However, the second component, Dydrogesterone, is a synthetic progestogen.

---

Q: Can I still get pregnant while taking Femaston?

Femaston is contraindicated during pregnancy and is not approved for use as a contraceptive. Official guidelines mention that if a woman is under 50 years old or it has been less than 12 months since her last period, the need for additional non-hormonal contraception should be considered.

---

Q: What does the term 'Estradiol' mean?

Estradiol is the primary oestrogen hormone naturally produced by the ovaries in women. The estradiol component in this medication is chemically and biologically identical to this natural human hormone.

---

Q: Are there any specific organs that Femaston is known to affect?

Official warnings and precautions mention effects on the uterus (where the progestogen protects the lining), the liver (as use is contraindicated in acute liver disease), and the cardiovascular system (due to the documented risks of VTE and stroke).

---

Q: If I have a history of migraines, can I still take Femaston?

Official documents list a history of migraine or severe headache as a condition for which treatment may require close supervision by a healthcare professional. These conditions may also require potential withdrawal of therapy if they worsen or occur frequently.

---

Q: Is it normal to have breast tenderness when starting Femaston?

Breast pain or tenderness is classified in regulatory documents as a Very Common side effect, affecting 1 in 10 or more people. This effect is generally related to the hormonal components and often settles after the first few months as the body adjusts to the therapy.

---

Q: What kind of monitoring is recommended for people using Femaston?

Regulatory documents recommend that during treatment, periodic check-ups are performed, with the frequency and nature adapted to the individual. Official documentation notes that women should be aware of changes in their breasts and know which ones to discuss with their healthcare provider, and the ongoing balance of risks and benefits should be formally reviewed at least annually.

How to Store and Dispose of Femaston (Estradiol)?

Proper storage and disposal are essential to maintain the efficacy and safety of Femaston tablets.

---

Storage Guidelines

Condition	Recommendation
Temperature	Store at room temperature (typically 20 C to 25 C or 68 F to 77 F), away from extreme heat or freezing.
Environment	Keep the tablets in their original container, protected from moisture and direct light.
Safety	Store out of the sight and reach of children and pets.

---

Disposal Guidelines

Do not dispose of unused or expired medication by flushing it down the toilet or throwing it in household trash unless specifically instructed to do so by a healthcare professional or regulatory body. The safest methods for disposal include:

• Drug Take-Back Programs: Participate in local drug take-back programs, which are the preferred method for disposal.
• Household Trash (if take-back is unavailable): Mix the medicine with an undesirable substance (like dirt or coffee grounds), place it in a sealed bag or container, and discard it with household trash. Scratch out all personal information on the prescription label before discarding the container.